EGFR and colorectal cancer: In 2012, research hotspots emerged around terms such as “Oral Fluoropyrimidines,” “Monoclonal-Antibody,” and “Controlled-Trial,” underscoring an increasing focus on optimizing chemotherapy delivery systems—particularly oral formulations—and molecular-targeted therapies, including anti-EGFR and VEGF agents, for colorectal cancer treatment.